{"id":3222,"date":"2026-09-16T00:00:00","date_gmt":"2026-09-16T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3222"},"modified":"2026-09-19T13:53:08","modified_gmt":"2026-09-19T17:53:08","slug":"prime-assembly-enables-large-targeted-dna-integration","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3222","title":{"rendered":"Prime Assembly Enables Large Targeted DNA Integration"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Boston Children’s Hospital and Collaborators<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Publication<\/p>\n

Modality<\/strong><\/p>\n

CRISPR-Targeted Dual-Flap Synthesis (“Prime Assembly”) for RNA-Programmable DNA Integration<\/p>\n

Disease Area<\/strong><\/p>\n

Platform Technology (Demonstrated in Dyskeratosis Congenita, TINF2)<\/p>\n

Summary<\/h4>\n

A Nature paper published online September 16 describes “prime assembly,” a CRISPR-targeted dual-flap synthesis method for RNA-programmable integration of single- or double-stranded DNA without a nuclease-driven double-strand break or cell-cycle dependence. The platform recoded a TINF2 dyskeratosis-congenita region, integrated transgenes as large as 12.1 kilobases, assembled multiple fragments, and functioned in primary T cells and CD34-positive hematopoietic stem and progenitor cells. Therapeutically relevant primary-cell efficiencies were low and no animal engraftment or treatment study was reported.<\/p>\n

In K562 cells, TINF2 exon recoding reached roughly 30% to 33%. At AAVS1, a 9.1-kilobase donor produced 28.1% reporter-positive cells and a 12.1-kilobase donor 7.4%. Four-fragment assembly could be enriched to 96% after drug selection. In primary CD34-positive cells from three donors, viability was 60.8% to 82.9% but integration averaged about 1.5% at AAVS1 and 1.3% at IL2RG. Resting and activated primary T-cell efficiencies were similarly low.<\/p>\n

Donor-seq found guide-dependent off-target integration up to 1.145% of unique reads for one TRAC guide and 0.734% for one AAVS1 site. Imprecise alleles, deletions, scaffold incorporation, and indels occurred. DNA-PK and polymerase-theta inhibitors improved precision and efficiency, creating an additional translational variable. The paper reports a related patent application; no clinical program or license was disclosed.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that prime assembly expands the genome-engineering design space by combining large payloads, non-dividing-cell activity, and avoidance of programmed double-strand breaks. Large cargoes, multi-fragment assembly, and primary-cell activity support that view. Against near-term therapeutic readiness, HSPC efficiency is around 1% to 2%, some gains rely on repair inhibitors, and selection cannot be assumed clinically. A second interpretation is that the method is currently more useful for research-cell engineering or ex-vivo applications with enrichment than direct treatment. The data support that narrower use, while future delivery and enzyme optimization could change it.<\/p>\n

Company and Product Background<\/h4>\n

The work was led by academic investigators including Boston Children’s Hospital and Harvard-affiliated groups. Prime editors use a Cas nickase–reverse-transcriptase fusion and guide RNAs to write DNA without a canonical double-strand break. Prime assembly extends this logic by generating complementary flaps that recruit donor fragments for cellular assembly. Dyskeratosis congenita caused by TINF2 mutations is a telomere disorder that can produce marrow failure, providing a relevant hematology demonstration rather than clinical validation.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Prime assembly is a substantive platform advance, especially for disease architectures requiring exon replacement or large transgenes.<\/li>\n
  • Upgrades with:<\/strong> reproducible editing of long-term repopulating human HSCs, multilineage engraftment, in-vivo correction, preserved stemness, clinically feasible delivery, clean long-read genotyping, and low unbiased off-target integration without repair inhibitors.<\/li>\n
  • Downgrades with:<\/strong> donor toxicity, p53 activation, chromosomal rearrangement, poor product purity, or loss of HSC fitness.<\/li>\n
  • Falsified if:<\/strong> efficiency and purity cannot rise in disease-relevant primary cells without damaging viability or stemness.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Prime assembly is a substantive platform advance, especially for disease architectures requiring exon replacement or large transgenes. The result should be treated as enabling biology rather than a treatment candidate. Primary-HSPC efficiency, genotoxicity, delivery, manufacturing, and IP control are the decisive bridge from elegant chemistry to medicine.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 — peer-reviewed platform expansion into large, targeted DNA insertion. Importance:<\/strong> Uncertain — technical capability is clear, but therapeutic feasibility is unresolved. Confidence:<\/strong> High on facts (full methods, quantitative experiments, and limitations are peer reviewed); moderate on interpretation (translation depends on primary-cell efficiency, safety, and delivery not yet shown).<\/p>\n","protected":false},"excerpt":{"rendered":"

    A Nature paper published online September 16 describes \u201cprime assembly,\u201d a CRISPR-targeted dual-flap synthesis method for RNA-programmable integration of single- or double-stranded DNA without a nuclease-driven double-strand break or cell-cycle dependence. The platform recoded…<\/p>\n","protected":false},"author":1,"featured_media":3245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[786,369,462],"class_list":["post-3222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-dyskeratosis-congenita","tag-gene-editing","tag-prime-editing"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3222"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3222\/revisions"}],"predecessor-version":[{"id":3248,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3222\/revisions\/3248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3245"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}